Upon viral infection, reduced FLAD1 activity lowered FAD amounts, which removed its inhibitory control over DNA and RNA sensors, thus facilitating extensive interferon-I (IFN-I) signaling activation and strengthening the innate immune response and protected mice from viral infection.
Abstract
Cytosolic DNA and RNA sensing is crucial for innate immunity, playing essential roles in pathogen defense and autoinflammation induction. We reported the endogenous metabolite flavin adenine dinucleotide (FAD) as a molecular brake restraining both cytosolic DNA and RNA sensing. It bound directly to cytosolic nucleic acid sensors cyclic GMP-AMP synthase (cGAS) and retinoic acid-inducible gene I (RIG-I), occupying catalytic pockets to suppress their activity and downstream immune responses. Physiologically, FAD prevented self-nucleic acid-induced sterile inflammation and maintained immune homeostasis. FAD deficiency due to FAD synthase (FLAD1) ablation exacerbated auto-inflammation and cellular senescence. Upon viral infection, reduced FLAD1 activity lowered FAD amounts, which removed its inhibitory control over DNA and RNA sensors, thus facilitating extensive interferon-I (IFN-I) signaling activation. Consequently, FLAD1 depletion strengthened the innate immune response and protected mice from viral infection. Our findings identify FAD as a natural suppressor of both cytosolic DNA and RNA sensing, offering therapeutic potential for inflammatory diseases.
Activation of cytosolic RNA and DNA sensing pathways that normally recognize viral nucleic acids triggers the expression and release of type I interferons (IFN-I). This release drives the expression of interferon-stimulated genes (ISGs) that activate acute inflammation and counteract viral replication at various stages...
Maleana G. White, Sergey Iordanskiy· International Journal of Mol...· 0 citations
This Review examines critical-target and cumulative-burden models, methods for ligand identification, biomarker-guided patient selection and therapeutic strategies based on viral mimicry, ADAR1 targeting, engineered dsRNA agonists, and delivery platforms.
Shao-Ping Li, Yan-Fei Huo, Hang-Wei Fa et al.· EBioMedicine· 0 citations
A ubiquitous RBP, YBX1, prevents noncoding RNAs synthesized by RNA polymerase III from being recognized as DAMPs under cellular homeostasis, preventing inappropriate activation of innate immunity.
Tania Strilets, Sarah Dremel, Mariano A. García-Blanco· Proceedings of the National...· 0 citations
Tumors exploit multifaceted strategies to survive and avoid destruction by the immune system. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) regulates double-stranded (ds)RNA metabolism by catalyzing the adenosine-to-inosine (A-to-I) change, which is one of the most prevalent RNA modifications in ma...
C. Cerboni, Stefano Petrai, M. Greco et al.· Critical reviews in oncology...· 0 citations
The therapeutic potential of targeting ZBP1- and IFI16-mediated pathways for anti-inflammatory and anti-infective strategies are covered and a balanced analysis of developmental challenges, potential toxicity, and risks of impaired immune surveillance is provided.